Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15763710 | 0.88 | CDK5 (0.48) | KDM4ECDK5CDK5R1TSHRMEN1 | |
| SCHEMBL22571139 | 0.84 | KDM4E (0.47) | KDM4ECDK5CDK5R1TSHRMEN1 | |
| SCHEMBL22765060 | 0.82 | KDM4E (0.48) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL10001689 | 0.82 | KDM4E (0.48) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL20052011 | 0.81 | KDM4E (0.47) | KDM4ECDK5CDK5R1TSHRMEN1 | |
| SCHEMBL20407788 | 0.81 | KDM4E (0.47) | KDM4ECDK5CDK5R1TSHRMEN1 | |
| SCHEMBL25652395 | 0.80 | KDM4E (0.43) | KDM4ECDK5CDK5R1TSHRMEN1 | |
| SCHEMBL22968405 | 0.80 | KDM4E (0.45) | KDM4ECDK5CDK5R1TSHRMEN1 | |
| SCHEMBL22091499 | 0.80 | KDM4E (0.47) | KDM4ETSHRMEN1KMT2ANOS1 | |
| SCHEMBL22462003 | 0.80 | KDM4E (0.47) | KDM4ETSHRMEN1KMT2ANOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| WO-2020117625-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | KDM4E 4039/4885CDK5 4831/4885CDK5R1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.